Jan H.M. Schellens

机构：Utrecht University · ORCID：0000-0001-6832-1976

发表论文 1184 篇 · 总被引 60828 次 · h-index 113

代表论文

• Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial (2023 · Nature Medicine · 被引 336)
• Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy—A Matched-Pair Analysis (2023 · Journal of Clinical Oncology · 被引 56)
• Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis (2024 · British Journal of Cancer · 被引 25)
• Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study (2025 · European Journal of Cancer · 被引 13)
• Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD (2024 · Genome Medicine · 被引 13)
• A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAF V600 -Mutated Melanoma (2024 · Clinical Cancer Research · 被引 13)